TNGNQ logo

Tengion Inc.

TNGNQ

Key details

CEO

-

Employees

19

Headquarters

null, null

Sector

Manufacturing

Industry

Biological Product (except Diagnostic) Manufacturing

About Tengion Inc.

tengion, a clinical-stage biotechnology company, has pioneered the organ regeneration platform™ that enables the company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. an initial clinical trial is ongoing for the company’s lead product candidate, the neo-urinary conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. the company’s lead preclinical program is the neo-kidney augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. tengion has also applied its techn

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG